Member Info for AquaeSulis01

Hi elrico, I do remember the history of SOH selling and the non-sticky fingers shares ending up in and shared in the criticism at the time. However, I think a dig at SOH because of the suspicion that the recent largish (in relation to normal trading size) is down to him and has caused the share price to fall from 17.5p to 13p, unnecessary and inconsequential. The cause of the falling share price is down to much wider issues than a once off sell by a large holder out of necessity, after all the share price decline from 55p at the last reported Opti sell to 17.5p has occurred despite SOH not selling a single share in Skin during that period.

Elrico, you are sounding more like a "bitter" everyday. It may well be that SOH is responsible for placing more shares into the market, but as to being the regular seller that Clio speaks of, the last share placing took place November 2021 and bearing in mind this was shortly followed by the following Results RNS set of missed targets

"Croda-SkinBiotix® programme continued to progress to plan, with focus on scaling up lysate manufacture to commercial volumes

· Potential additional cosmetic claims for SkinBiotix® being investigated. Initial royalty revenues anticipated as planned in calendar year 2022

Post year end:

· Successful product launch of AxisBiotix-Ps™ 12 months earlier than intended. Early sales in the UK and US have commenced; expansion into Europe to occur in H1 2022

· Targeting acne as the next AxisBiotix opportunity; plans to develop a bacterial blend and initiate a consumer study during 2022"

SOH has probably been remarkably patient before selling more of a non-core asset.

Rather than blaming the Opti (Man Utd) CEO for the continuing share price demise because he maybe sees this as the least painful way of raising funds to strengthen his own "Team" perhaps the focus should be on what the Skin CEO needs to do to improve the prospects here to hit targets that have been set, although of course matters may be taken out of his hands if new owners with deep pockets for Skin (Man City) move in with an acquisition offer, aka Croda, if prospects appear as bright as they sound.

Wonder if the big seller is through now; million shares dumped at 13p

Mol, you have got hold of the wrong end of the stick. Opti' has not changed its auditor, but because of their merger with other groups, the start of the audit will have been delayed whilst they determined which companies they would still be able to and wish to act for. Expect the audit to complete in time for end of this month's date but didn't enable the company to publish unaudited figures in advance which would still need to be OK'd by the auditors

For those that questioned the reason for the lack of an unaudited FY update being down to the fact that the auditors had changed ownership, worth noting the impact the change had on the capacity of Jeffrey's to carry out their audity responsibilities from the Deepverge RNS today "Possibility of delay to the announcement of the results for the year ended 31 December 2022 and publication of the Annual Report

The possibility of delay is caused, inter alia, by the resignation of the Group's previous auditor, Jeffreys Henry LLP, as announced on 24 March 2023. Following a change of ownership and name, Jeffreys Henry LLP undertook a review of its capacity to undertake audit work, in conjunction with the Institute of Chartered Accountants in England and Wales which concluded that the firm did not have sufficient capacity to satisfy its regulatory requirements and as a result resigned as auditor to a number of quoted companies, including DeepVerge.

The resignation of Jeffreys Henry occurred just days before the audit of DeepVerge's accounts was due to start. Haysmacintyre LLP was subsequently appointed as the Company's auditor, however there is significant risk of there being insufficient time to ensure that the audit is completed by 30 June 2023."

Short term probably not the best choice of words bogyo, but was referring to the recent, in my view, illogical selling in terms of present company value.

Whilst the 5 year picture does not make pretty viewing, this share can move very quickly when it reaches rock bottom on good news, as demonstrated between 18/03/20- 21/05/20 when the price moved from 24p to 68p. I take the view that in financial terms we know what to expect from a dismal 2022, as does the market, so lets see what 2023 and beyond promises to delivery.

Bit more insight

https://mixed-news.com/en/juicy-apple-xr-headset-details-leak-days-before-a-possible-wwdc-reveal/

"Apple XR headset display specifications

According to Ross Young, CEO of Display Supply Chain Consultants, Apple’s XR headset will feature micro-OLED displays that exceed 5,000 nits of peak brightness. By comparison, the panels of an iPhone 14 Pro reach a maximum of 2,000 nits.

It should be noted that the brightness that reaches the eye could be significantly reduced, depending on the lenses used in Apple’s headset. The glass screen of an iPhone lets nearly all light pass, but to allow you to focus on a screen that’s about an inch from your eye, a special lens is needed, resulting in much lower brightness.

Young also stated the display resolution was 4K per eye with a 4,000 pixel-per-inch density. This could be the sharpest image ever seen in a consumer headset, even eclipsing the Varjo Aero. Each eye is said to have a 1.41″ display, which is large enough for a good field of view (FOV), depending on the lenses used."

Https://www.cnbc.com/2023/06/01/why-apples-headset-could-become-the-first-vr-success-story.html

"On Monday, Apple

is expected to announce its first new major product line since the Apple Watch in 2014.

During Apple’s software-focused developer conference, WWDC, it could release its first mixed-reality headset, according to analyst research, media reports and increasingly, vague references from Apple itself.

The headset, according to reports, will feature high-definition screens in front of the user’s eyes. But it could also let users see and interact with the real world through high-powered cameras mounted on the device, a trick sometimes called passthrough or mixed reality."

As a relative newcomer here, I presume that the hope is that as Apple was believed to be planning to use Nanoco’s technology for an advanced image sensor that was set to feature in the Iphone’s camera before the contract was cancelled, the QDs will now find a home in the VR Headset, in which case Monday's Apple presentation will be bvery interesting?

https://www.prolificnorth.co.uk/news/tech-news/2019/06/manchesters-nanoco-loses-three-quarters-its-value-after-apple-cancellation

Let's wait for the EOY Reports for both PBX and Opti before reading the last rites Friedman. What we do know is that PBX had a much better 2022 than Opti and hence its current value is more to do with the sale of relatively few shares on the illiquid AQSE market rather than its performance and hence we can expect a re-rate in its value and in turn Opti's holding in the not too distant future meaning Opti will be valued less than its assets if the price remains the same.

Also, additional Partners have been added for Opti's first generation products with further US Partners expected to be onboarded in the next few months, online sales have increased significantly, and the promising outlook for 2023 may well be given a boost with anticipated soft launches for both 2nd generation products, sweebiotix and microbiome modulators , towards the end of the year.

Additionally, SOH has finally taken action to reduce overhead costs with one Director already gone, the Board taking a 20% reduction in salary in Jan 2023, and two more non-executives expected to leave following approval at the AGM raising the prospect that finally Opti will operate at a profit and hence wont need to sell assets to keep the lights on, only to grow the business and pay dividends to long suffering holders when the time is right.

So, sit tight, ignore the short term pain and as they say Rodney "This time next year...."

I hope you are right chilting, the signing of the JV was always supposed to be a precursor for the main listing application , from 17th Nov 2022 RNS

"TIMING OF CHINA JV AGREEMENTS DELAYED UNTIL 2023

Horsham, UK: The Directors of Ceres Power Holdings plc ("Ceres", the "Company") (AIM: CWR.L), were informed last night that the negotiations will not conclude this year and approvals for the joint venture (JV) agreements with Robert Bosch GmbH and Weichai Power have been postponed until 2023.

All parties remain committed to the deal, the structure of which has been agreed. There are several commercial items remaining which require more time to be finalised between the partners. Ceres will update the market further on progress as appropriate.

Accordingly, this will delay Ceres' intention to seek a Premium Listing on the Main Market of the London Stock Exchange."

Will be interesting to see how SOH chooses to present the EOY figures bearing in mind the artificially high figures caused by overstocking in 2021 which led to the uptick in 2020 full year sales and the subsequent lack of orders from big partners in H1 2022

. A comparison with 2020 prebiotix sales will show more or less flat sales rather than the 50% drop when compared to 2021

PREBIOTIX

2020 FY 2021 FY 2022 FY

1st Half 2nd Half Whole Year 1st Half 2nd Half Whole Year 1st Half 2nd Half Whole Year

£342,734.00 £214,805.00 £557,539.00 £539,819.00 £560,181.00 £1,100,000.00 £118,898.00 £431,102.00 £550,000.00

Hi martinu, you are not misinterpreting anything, I have; I used the Opti h1 figures which I misread to include combined revenue sales for the H1 2022 when it was for 2021 (SOH didn't bother to extract just the Opti prebiotix figures which were available for 2021 for a straight comparison (£539,819) versus £118,898 for 2022.

Not quite such a rosy picture although PBX looks to have had a far stronger H2 recovery than Opti which will lead to higher annual figures than 2021 of I guesstimate in the region of £1.5M giving combined PBX and Opti sales of circa £2,056,042 which is 6.5% lower than the 2021 FY combined total. Should still lead to a nice re-rate of PBX and hence the value of Opti's holding

Let's get the bad news out of the way first, revenues for Opti Prebiotix 2022 are likely to be down 50% on 2021. However, bearing in mind Opti owns 44% of PBX and its share price and Market Cap do not represent performance there, the good news is PBX EOY Results are likely to be up circa 78% on 2021 meaning the collective Company Revenues for 2022 actually rise by circa 14%. SOH cautiously advises much better things for both companies in 2023 and interpretation of the forecast presentation slide shows project revenue of £1.750M which will represent a 218% increase on 2022 for Opti alone.

The H1 2021 figure for the Probiotix side of the business were £536,181 whilst largely went unnoticed, H1 2022 figure for PBX was £957,146 which was a 78.51% increase and we have been told to expect more of the same for H2 2022 with further rises in 2023. H1 for Opti Prebiotix in 2021 was £539,819 with H2 recording £560,181. 2022 H1 was a pitiful £118,898 with H2 from the slide appearing to show a year total of circa £550K meaning a H2 recovery to circa £431,102.

Combined revenues for the two companies are likely to be in the region of £2,507,000 as opposed to £2,200,000 for 2021.

Ria, you obviously know very little about the companies you trade in so what or who brought skinbiotherapeutics to your attention?

Pay cut not patchy

You would have realised two of my four questions were answered and that all the Board took a 20% patchy in January and two of the four NEDs will be leaving if ratified at the AGM for starters

mol, why comment on an investor meets presentation when you have only listened to 10 mins? do yourself a favour and listen to it all properly before going off half ****ed

Ria, the increase in the VRS share price will certainly enable the company to bring forward its bi-monthly placing and keep the lights on a little longer which is a positive, and I multi bagged yesterday as I picked 4/1 and 3/1 winners at Yarmouth races with my only two bets but recognise I could just as easily lost my stakes, but hey that is what gambling is all about isn't it?

As for Italy, if it brings forward the Multi partner agreement announcement then bring it on because it is that agreement that will at as a catalyst for the share price

One correction, optipharma spending 50k dollars not 50m

Have now taken the time to watch the recording of the presentation again, highlights and Lowlights as follows:

- Turnover Chart - 2021 SLimbiome + GoFigure Sales were circa £1M and the Sweetbiotix milestone payment 0.100M

- 2022 Slimbiome + GoFigure unaudited figures look to be circa £0.450M and the sweetbiotix £0.100M

-2023 Total Forecast circa £1.750M

- Optipharm are spending $50M per month marketing the new Opti products; Optiwoman, Optivegan and Ready Meal Sachets

- Apollo Hospitals Doubled sales between March 2023 and April 2023

- New US Partner (similar size to THG) has launched leanbiome, details next month or so with two further US Customers going through the order process

- THG forecasted taht they would order 7 metric tonnes of leanbiome and took only 0.5 metric tonnes (1 metric tonne costs £30K)

-The Hull Clinical Study for Wellbiome to see whether it can speed up patient recovery rates going ahead; Hull have purchased some wellbiome, it has gone through ethics approval and candidates are currently being recruited

- Online sales increased 1200% between Oct 2022 - April 2023 e.g. Slimbiome Medical now makes up 6% of all online sales, 25 boxes sold in October 2022 whilst 340 boxes were sold in April 2023

-sweetbiotix

- US Partner produced optimised scaled-up version in liquid form Dec 2022 and has now produced it freeze dried May 2023. Taste is fine but novel structure being scrutinised and finalised to ensure it can be properly protected by patents whilst not being too novel to prolong regulatory approval (data feedback expected to be released next couple of months). Soft launch 2023 using Optibiotix own products (such as wellbiome) to trial it with full launch in 2024.

- Firminech have already scaled up from a lab yield of 5% to achieve a yield of 50%, a 70% yield is the target for launch readiness